Azenta, Inc.
Rank #415StartupAZTA · Nasdaq · Healthcare
Azenta, Inc. (AZTA) — Rank #415 by gross profitability (GP/assets 0.14) · ROE -3.7% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0000933974 · all metrics point-in-time as of the filing date.
About
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
Show moreShow less
It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc.
was founded in 1978 and is headquartered in Burlington, Massachusetts.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- September 30
- Website
- azenta.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilityimproving
- Net cashdeteriorating
- Operating margindeteriorating
- Return on equitydeteriorating
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-09-30filed 2025-12-04 | 2024-09-30filed 2024-11-27 | 2023-09-30filed 2023-11-21 | 2022-09-30filed 2022-11-25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 593.8 | 656.3 | 665.1 | 555.5 |
| Revenue growth (YoY) | 3.6% | -1.3% | 19.7% | 8.1% |
| Gross profit | 270.3 | 263.4 | 263.1 | 255.6 |
| Gross margin | 45.5% | 40.1% | 39.6% | 46.0% |
| Net income | (55.8) | (164.2) | (14.3) | 2,132.9 |
| Net margin | -9.4% | -25.0% | -2.1% | 384.0% |
| EPS (diluted) | -$1.22 | -$3.09 | -$0.22 | $28.48 |
| EPS growth (YoY) | 60.5% | -1304.5% | -100.8% | — |
| Cash flow | ||||
| Operating cash flow | 72.2 | 50.3 | 17.5 | (466.0) |
| Capital expenditures | 33.9 | 37.4 | 39.4 | 73.4 |
| Free cash flow | 38.3 | 12.9 | (21.9) | (539.5) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?